Analysis of Long-term (Investment) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
GlaxoSmithKline PLC, long-term (investment) activity ratios
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | GlaxoSmithKline PLC net fixed asset turnover ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | GlaxoSmithKline PLC total asset turnover ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | GlaxoSmithKline PLC equity turnover ratio deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level. |
Net Fixed Asset Turnover
GlaxoSmithKline PLC, net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions, translated from GBP £) | ||||||
| Turnover | 38,855) | 43,926) | 42,984) | 42,553) | 43,700) | |
| Property, plant and equipment | 15,288) | 14,703) | 14,272) | 13,592) | 13,922) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 2.54 | 2.99 | 3.01 | 3.13 | 3.14 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Net fixed asset turnover = Turnover ÷ Property, plant and equipment
= 38,855 ÷ 15,288 = 2.54
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | GlaxoSmithKline PLC net fixed asset turnover ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
Total Asset Turnover
GlaxoSmithKline PLC, total asset turnover calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions, translated from GBP £) | ||||||
| Turnover | 38,855) | 43,926) | 42,984) | 42,553) | 43,700) | |
| Total assets | 68,656) | 69,748) | 67,450) | 63,828) | 64,999) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.57 | 0.63 | 0.64 | 0.67 | 0.67 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Total asset turnover = Turnover ÷ Total assets
= 38,855 ÷ 68,656 = 0.57
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | GlaxoSmithKline PLC total asset turnover ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
Equity Turnover
GlaxoSmithKline PLC, equity turnover calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions, translated from GBP £) | ||||||
| Turnover | 38,855) | 43,926) | 42,984) | 42,553) | 43,700) | |
| Shareholders’ equity | 7,200) | 11,596) | 9,449) | 12,480) | 13,679) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 5.40 | 3.79 | 4.55 | 3.41 | 3.19 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Equity turnover = Turnover ÷ Shareholders’ equity
= 38,855 ÷ 7,200 = 5.40
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | GlaxoSmithKline PLC equity turnover ratio deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level. |